The Research group of Sankalp Speciality Hospital is young strong headed panel of super specialist working in the area of Nashik and north Maharashtra region. The group is headed by Dr. Bhushan Nemade (MD, PDCR) who himself is Oncologist working in the field of research for more than 8-10 years.
The entire group is committed to conduct Clinical research according to ICH GCP and ICMR guidelines.
To facilitate quality clinical research for effective and efficient evaluation of new pharmaceutical investigational product.
A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer.
Open Label Randomized study of two different rituximab as monotherapy of CD 20 positive indolent Non Hodgkin Lymphoma.
Phase II Study of Masatinib with Docetexel in hormone Refractory Prostate Cancer
Phase III Study of Masatinib in combination with gemcitabine to gemcitabine with placebo followed by second line treatment by masitinb in combination with FOLFIRI 3 vs placebo in combination with FOLFIRI 3 in treatment of patients with non resectable locally advanced or metastatic Ca pancreas.
A prospective, multicenter, randomized, double blind, placebo-controlled,2-parallel groups, phase 3 study to compare the efficacy and safety of(masitinib in combination with irinotecan, 5-fluorouracil and folinic acid (FOLFIRI)) to (placebo in combination with FOLFIRI) in second line treatment of patients with metastatic colorectal cancer.
A randomised double-blind study Comparing two humanized monoclonal antibodies that target VEGF incombination with mFOLFOX6 in patients with non-resectable metastatic colorectalcancer (mCRC)
Phase I study of cetuximab compared with Innovator in locally advanced Head beck cancer not fit for radical chemoradiation.
A randomised double-blind study Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC).